NEW YORK, Feb 15 – Due to strong sales of its MassArray SNP analysis technology, Sequenom reported increased revenues for the fourth quarter and year-end Thursday

.Sequenom’s fourth quarter revenues totaled $3.7 million, compared with $98,000 for the year-ago quarter, and year-end revenues totaled $10 million, compared with $179,000 for 1999.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.